NurExone CEO to speak at Exosome — Based Therapeutics Development Summit

NurExone will attend four Boston life sciences conferences from Sept. 22-25, 2026 to market its exosome-therapy programs. CEO Dr. Lior Shaltiel is scheduled to speak at the Exosome-Based Therapeutics Development Summit on Sept. 22-24. Shaltiel will also join an LSX Congress USA panel on Sept. 23. * BioProcess International will feature a Shaltiel presentation on Sept. 25 on exosome bioprocessing, manufacturing scale-up, drug-delivery applications. Shaltiel is set to attend the invitation-only World Medical Innovation Forum on Sept. 22-23. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via (Ref. ID: 202609181621PRIMZONEFULLFEED9829830) on September 18, 2026, and is solely responsible for the information contained therein. (C)